Agarwal Tarun, Narayana S N Gautham Hari, Pal Kunal, Pramanik Krishna, Giri Supratim, Banerjee Indranil
Department of Biotechnology and Medical Engineering, National Institute of Technology, Rourkela Odisha 769008, India.
Department of Chemistry, National Institute of Technology, Rourkela Odisha, 769008, India.
Int J Biol Macromol. 2015 Apr;75:409-17. doi: 10.1016/j.ijbiomac.2014.12.052. Epub 2015 Feb 10.
The present study delineates preparation, characterization and application of calcium alginate (CA)-carboxymethyl cellulose (CMC) beads for colon-specific oral drug delivery. Here, we exploited pH responsive swelling, mucoadhesivity and colonic microflora-catered biodegradability of the formulations for colon-specific drug delivery. The CA-CMC beads were prepared by ionic gelation method and its physicochemical characterization was done by SEM, XRD, EDAX, DSC and texture analyzer. The swelling and mucoadhesivity of the beads was found higher at the simulated colonic environment. Variation was more prominent in compositions with lower CMC concentrations. CA-CMC formulations degraded slowly in simulated colonic fluid, however the degradation rate increased drastically in the presence of colonic microflora. In vitro release study of anticancer drug 5-fluorouracil (5-FU) showed a release (>90%) in the presence of colonic enzymes. A critical analysis of drug release profile along with FRAP (fluorescence recovery after photobleaching) study revealed that the presence of CMC in the formulation retarded the release rate of 5-FU. 5-FU-loaded formulations were tested against colon adenocarcinoma cells (HT-29). Cytotoxicity data, nuclear condensation-fragmentation and apoptosis analysis (by flow cytometry) together confirmed the therapeutic potential of the CA-CMC formulations. In conclusion, CA-CMC beads can be used for colon-specific drug delivery.
本研究描述了用于结肠特异性口服给药的海藻酸钙(CA)-羧甲基纤维素(CMC)微球的制备、表征及应用。在此,我们利用了制剂的pH响应性溶胀、粘膜粘附性以及结肠微生物群介导的生物降解性来实现结肠特异性药物递送。通过离子凝胶法制备了CA-CMC微球,并通过扫描电子显微镜(SEM)、X射线衍射(XRD)、能谱分析(EDAX)、差示扫描量热法(DSC)和质构分析仪对其进行了物理化学表征。发现微球在模拟结肠环境中的溶胀和粘膜粘附性更高。在较低CMC浓度的组合物中,这种变化更为显著。CA-CMC制剂在模拟结肠液中降解缓慢,然而在结肠微生物群存在的情况下,降解速率急剧增加。抗癌药物5-氟尿嘧啶(5-FU)的体外释放研究表明,在结肠酶存在的情况下释放率>90%。对药物释放曲线的严格分析以及光漂白后荧光恢复(FRAP)研究表明,制剂中CMC的存在延缓了5-FU的释放速率。对负载5-FU的制剂进行了针对结肠腺癌细胞(HT-29)的测试。细胞毒性数据、核浓缩-碎片化和凋亡分析(通过流式细胞术)共同证实了CA-CMC制剂的治疗潜力。总之,CA-CMC微球可用于结肠特异性药物递送。